Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment

BioSystems

Volumn 111, Issue 2, 2013, Pages 71-82

  Ling, Hong ^a   Samarasinghe, Sandhya ^a   Kulasiri, Don ^a  

^a LINCOLN UNIVERSITY   (New Zealand)

Author keywords

Cancer; Cell cycle regulation; Cellular senescence; Computational models; DNA damage signal transduction pathway; G1 S checkpoint pathway; Senescence pathway; Systems biology

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; DNA; PROTEIN P21;

CANCER; CYTOLOGY; DNA; EXPERIMENTAL STUDY; NUMERICAL MODEL; SENESCENCE; SIGNAL;

ARTICLE; CANCER THERAPY; CELL AGING; CELL CYCLE ARREST; CELL DAMAGE; CELL POPULATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; PROTEIN DEGRADATION; PROTEIN TARGETING; QUALITATIVE ANALYSIS; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 84872669396     PISSN: 03032647     EISSN: 18728324     Source Type: Journal    
DOI: 10.1016/j.biosystems.2012.12.001     Document Type: Article

References (44)

1. kip1 in retinoblastoma protein-mediated senescence. Mol. Cell. Biol. 2001, 21(11):3616-3631.
2. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol. 2010, 12(1):54-59.
3. Campaner S., Doni M., Verrecchia A., Fagà G., Bianchi L., Amati B. Myc, Cdk2 and cellular senescence: old players, new game. Cell Cycle 2010, 9(18):3655-3661.
4. Campisi J., Fabrizio d.A.d.F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8(9):729-740.
5. Ciliberto A., Novak B., Tyson J. Steady states and oscillations in the p53/Mdm2 network. Cell Cycle 2005, 4(3):488-493.
6. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130(2):223-233.
7. Kip1. J. Biol. Chem. 2000, 275:21960-21968.
8. Collado M., Serrano M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 2010, 10(1):51-57.
9. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 2003, 13(2):65-70.
10. Coverley D., Pelizon C., Trewick S., Laseky R.A. Chromatin bound Cdc6 persists in S and G2 phases in human cells, while soluble Cdc6 is destroyed in a cyclin A-cdk2 dependent process. J. Cell Sci. 2000, 113:1929-1938.
11. Denicourt C., Dowdy S.F. Cip/Kip proteins: CDKs inhibitors. Genes Dev. 2004, 18:851-855.
12. Dulic V., Kaufmann W.K., Wilson S.J., Tisty T.D., Lees E., Harper J.W., Elledge S.J., Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76(6):1013-1023.
13. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
14. Fang L., Igarashi M., Leung J., Sugrue M.M., Lee S.W., Aaronson S.A. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 1999, 18:2789-2797.
15. Geva-Zatorsky N., Rosenfeld N., Itzkovitz S., Milo R., Sigal A., Dekel E., Yarnitzky T., Liron Y., Polak P., Lahav G., Alon U. Oscillations and variability in the p53 system. Mol. Syst. Biol. 2006, 2.
16. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., Hendrickson E.A., Balan K.V., Pantazis P., Wyche J.H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 2002, 277(19):17154-17160.
17. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
18. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25(3):585-621.
19. Hiebert S.W., Chellappan S.P., Horowitz J.M., Nevins J.R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 1992, 6(2):177-185.
20. Hydbring P., Bahram F., Su Y., Tronnersjö S., Högstrand K., von der Lehr N., et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(1):58-63.
21. Hydbring P., Larsson L.-G. Cdk2: a key regulator of the senescence control function of Myc. Aging 2010, 2(4):244-250.
22. Iwamoto K., Tashima Y., Hamada H., Eguchi Y., Okamoto M. Mathematical modelling and sensitivity analysis of G1/S phase in the cell cycle including the DNA-damage signal transduction pathway. Biosystems 2008, 94(1-2):109-117.
23. Jacobs J.J., de Lange T. Significant role for p16(INK4a) in p53-independent telomere-directed senescence. Curr. Biol. 2004, 14:2302-2308.
24. Lahav G., Rosenfeld N., Sigal A., Geva-Zatorsky N., Levine A.J. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. 2004, 36:147-150.
25. Lev Bar-Or R., Maya R., Segel L.A., Alon U., Levine A.J., Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(21):1250-11255.
26. Li G., Ho V.C. p53-Dependent DNA repair and apoptosis respond differently to high- and low-dose ultraviolet radiation. Br. J. Dermatol. 1998, 139(1):3-10.
27. Lin H.-K., Chen Z., Wang G., Nardella C., Lee S.-W. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464(7287):374-379.
28. Ling H., Kulasiri D., Samarasinghe S. Robustness of G1/S checkpoint pathways in cell cycle regulation based on probability of DNA-damaged cells passing as healthy cells. Biosystems 2010, 101(3):213-221.
29. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 1998, 18:753-761.
30. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9(3):153-166.
31. Obaya A.J., Sedivy J.M. Regulation of cyclin-Cdk activity in mammalian cells. Cell. Mol. Life Sci. 2002, 59:126-142.
32. Ohtani K. Implication of transcription factor E2F in regulation of DNA replication. Front. Biosci. 1999, 4:d793-d804.
33. Ohtani N., Mann D.J., Hara E. Cellular senescence: its role in tumor suppression and aging. Cancer Sci. 2009, 100(5):792-797.
34. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28(33):2925-2939.
35. Serrano M. Cancer: a lower bar for senescence. Nature 2010, 464(7287):363-364.
36. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
37. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18:2699-2711.
38. Stein G.H., Drullinger L.F., Soulard A., Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 1999, 19:2109-2117.
39. Tashima Y., Hanai T., Hamada H., Okamoto M. Simulation for detailed mathematical model of G1-to-S cell cycle phase transition. Genome Inform. 2004, 9.
40. van Riggelen J., Felsher D.W. Myc and a Cdk2 senescence switch. Nat. Cell Biol. 2010, 12(1):7-9.
41. Vergel M., Marin J.J., Estevez P., Carnero A. Cellular senescence as a target in cancer control. J. Aging Res. 2010, 2011:725365.
42. Vijg J., Dollé M.E.T. Large genome rearrangements as a primary cause of aging. Mechanisms of Ageing and Development 2002, 123(8):907-915.
43. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81(3):323-330.
44. Xu H.J., Zhou Y., Ji W., Perng G.S., Kruzelock R., Kong C.T., Bast R.C., Mills G.B., Li J., Hu S.X. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 1997, 15:2589-2596.